Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Notoginsenoside R1 is a major bioactive saponin compound isolated from the roots of *Panax notoginseng*, a traditional Chinese medicinal herb. It is classified as a panaxatriol saponin and is unique to *Panax notoginseng*[1][6][7]. Notoginsenoside R1 is not itself a pharmaceutical drug, but a pharmacologically active natural product and a commonly studied constituent of many traditional Chinese medicine products including Xuesaitong, Naodesheng, XueShuanTong, ShenMai, and QSYQ[1][5][6]. Notoginsenoside R1 exhibits multiple biological activities, including cardiovascular protection, neuroprotection, anti-inflammatory, anti-apoptotic, anti-oxidative, anti-ischemia-reperfusion injury, liver protection, gastrointestinal protection, lung protection, bone metabolism regulation, renal protection, and anti-cancer effects[1][5][6][7][3]. Reported mechanisms of action include modulation of inflammation and signaling pathways such as upregulation of estrogen receptor α-dependent PI3K/AKT and NRF2, downregulation of nuclear factor-κB (NF-κB) and MAPK pathways, inhibition of matrix metalloproteinase activity, regulation of cytokine expression (including IL-6, TNF, MMP9), and preferential neuroprotection via interactions with NMDA receptors containing NR1/NR2B subunits[1][2][3][7]. Clinical evidence is largely preclinical and further studies are needed for high-quality clinical confirmation[6]. Notoginsenoside R1 has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an apoptosis modulator, and a phytoestrogen[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on notoginsenoside R1.